21.54
2.32%
-0.5232
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Viridian Therapeutics Inc Borsa (VRDN) Ultime notizie
Brokers Set Expectations for Viridian Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Given New $44.00 Price Target at Royal Bank of Canada - MarketBeat
RBC raises Viridian Therapeutics shares price target, maintains Outperform rating - Investing.com UK
Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $31.00 - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Shares Up 4.8% on Analyst Upgrade - MarketBeat
Trend Tracker for (VRDN) - Stock Traders Daily
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock - BioSpace
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock - StockTitan
Viridian Therapeutics Says Selling 10.7 Mln Shares Of Common Stock At $18.75 Per Share - XM
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock - Business Wire
Viridian Therapeutics launches $150 million public offering - Investing.com India
VRDN Stock Soars as Eye Disorder Study Meets Primary Endpoints - Nasdaq
Needham & Company LLC Increases Viridian Therapeutics (NASDAQ:VRDN) Price Target to $38.00 - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Sees Unusually-High Trading Volume After Analyst Upgrade - MarketBeat
B.Riley raises Viridian Therapeutics shares target on Phase III THRIVE study - Investing.com Canada
VRDN Stock Soars as Eye Disorder Study Meets Primary Endpoints - Zacks Investment Research
Needham raises Viridian stock price target, maintains Buy rating By Investing.com - Investing.com Canada
Viridian Therapeutics’ stock jumps after Phase III trial met all endpoints - Clinical Trials Arena
Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load? - Simply Wall St
Viridian Therapeutics’ stock jumps after Phase III trial met all endpoints - Yahoo Finance
Viridian Therapeutics reports positive results for veligrotug - The Pharma Letter
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock - BioSpace
After-hours movers: GameStop, Dave & Buster's, Viridian Therapeutics By Investing.com - Investing.com Canada
Viridian’s Veligrotug Poses Formidable Challenge For Amgen’s Tepezza In TED - Scrip
Viridian Therapeutics (NASDAQ:VRDN) Earns "Buy" Rating from HC Wainwright - MarketBeat
Items Tagged with 'veligrotug' - BioWorld Online
Why are Viridian Therapeutics shares on the rise on Tuesday? - Mugglehead
Viridian Therapeutics launches $150 million public offering - Investing.com
Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way (NASDAQ:VRDN) - Seeking Alpha
Viridian Thrives on phase III with veligrotug in thyroid eye - BioWorld Online
After-hours movers: GameStop, Dave & Buster's, Viridian Therapeutics By Investing.com - Investing.com South Africa
How This Amgen Rival Is Taking On The Company's $28 Billion Acquisition - Investor's Business Daily
After-hours movers: GameStop, Dave & Buster's, Viridian Therapeutics - Investing.com India
Viridian Therapeutics launches $150 million public offering By Investing.com - Investing.com UK
Critical Insights From Viridian Therapeutics Analyst Ratings: What You Need To Know - Benzinga
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock - StockTitan
Viridian stock jumps on data for lead asset (NASDAQ:VRDN) - Seeking Alpha
Viridian Therapeutics stock gains confidence with improved efficacy and safety data - Investing.com
Viridian Therapeutics price target raised to $40 from $33 at Stifel - TipRanks
Viridian Therapeutics stock gains confidence with improved efficacy and safety data - Investing.com UK
BTIG Research Boosts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $56.00 - MarketBeat
Viridian Therapeutics (VRDN) Shares Cross Above 200 DMA - Nasdaq
Biotech Stock Scores Big Win, Squeezes Shorts - Schaeffers Research
Viridian Spikes On A 'Bull-Case Scenario' For Eye Drug Considered Amgen Rival - MSN
Viridian's drug cuts thyroid eye disease symptoms in late-stage study - Reuters
Viridian Therapeutics’ eye disorder treatment meets main goal in late-stage study - WKZO
Viridian Spikes On A 'Bull-Case Scenario' For Eye Drug Considered Amgen Rival - Inkl
Financial Snapshot: Analyzing Viridian Therapeutics Inc (VRDN)’s Key Ratio Metrics - The Dwinnex
Viridian Therapeutics Inc (VRDN)’s stock performance: a year in review - US Post News
Why Is Viridian Therapeutics Stock Trading Higher On Tuesday?Viridian Therapeutics (NASDAQ:VRDN) - Benzinga
VRDNViridian Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Viridian Therapeutics Shares Rise on Positive Results of Veligrotug in Thyroid Eye Disease Trial - MarketWatch
Viridian Therapeutics rises as eye disorder treatment meets main goal in late-stage study - XM
Viridian Therapeutics’ Veligrotug Triumphs in THRIVE Trial - TipRanks
Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease - StockTitan
Viridian Therapeutics launches $150 million public offering By Investing.com - Investing.com Canada
Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024 - StockTitan
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Bought by Candriam S.C.A. - MarketBeat
Viridian Therapeutics Inc (VRDN) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Market Momentum: Viridian Therapeutics Inc (VRDN) Registers a -9.23 Decrease, Closing at 13.47 - The Dwinnex
Viridian Therapeutics (NASDAQ:VRDN) Shares Down 6.3% - MarketBeat
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance UK
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Viridian Therapeutics (NASDAQ:VRDN) Shares Up 2.9% - MarketBeat
You might want to take a look at Viridian Therapeutics Inc (VRDN) now - SETE News
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $31.20 Consensus Price Target from Brokerages - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Receives Buy Rating from Needham & Company LLC - Defense World
Viridian Therapeutics shares hold Buy rating from Needham, focus on upcoming Phase 3 trial outcomes - Investing.com Australia
Viridian Therapeutics (NASDAQ:VRDN) Stock Rating Reaffirmed by Needham & Company LLC - MarketBeat
Viridian Therapeutics: Key Inflection Points Ahead (NASDAQ:VRDN) - Seeking Alpha
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):